Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline.

Pfizer (NYSE:PFE) reported lower fourth-quarter revenue as demand for its COVID-19 treatments continued to fade, but stronger ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental COVID-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...

NEW YORK -- When Laura Martin tested positive for COVID-19 last month during an extended stay in California, she was prescribed Paxlovid, the highly touted antiviral drug created by Pfizer. Just one ...

GENEVA (AP) - Nearly three dozen companies worldwide will soon start making generic versions of Pfizer's coronavirus pill, the U.N.-backed Medicines Patent Pool that negotiated the deal said Thursday.

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

In a surprising turn of events, Pfizer has reported fourth-quarter results that exceeded Wall Street's expectations, despite facing challenges due to declining demand for its COVID-19 products. This ...

Pfizer announced Wednesday it has begun phases 2 and 3 of its pediatric clinical trial for Paxlovid, its COVID-19 antiviral treatment. The study will look into how effective and safe the treatment is ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

Pfizer has signed a licensing deal to allow dozens of lower-income countries to benefit from generic versions of its new COVID-19 pill. The agreement covers 95 nations, but it omits some hard-hit ...